Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque

Vaccine

Volumn 33, Issue 37, 2015, Pages 4683-4690

  Edens, Chris ^a   Dybdahl Sissoko, Naomi C ^b   Weldon, William C ^b   Oberste, M Steven ^b   Prausnitz, Mark R ^a,c  

^a Emory University   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c Georgia Institute of Technology   (United States)

Author keywords

Inactivated polio vaccine; Microneedle patch; Poliomyelitis; Rhesus macaque; Sharps waste; Vaccination

Indexed keywords

INACTIVATED POLIO VACCINE; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE CLEARANCE; DRUG DELIVERY DEVICE; DRUG SAFETY; FEMALE; IMMUNOGENICITY; MASS IMMUNIZATION; MICRONEEDLE PATCH; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RHESUS MONKEY; SEROCONVERSION; VACCINATION; ANIMAL; BLOOD; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MODELS, ANIMAL; POLIOVIRUS VACCINE, INACTIVATED; TREATMENT OUTCOME;

EID: 84940451798     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.089     Document Type: Article

References (43)

1. Rodriguez-Alvarez M., Jimenez-Corona M.E., Cervantes-Rosales R., Ponce de Leon-Rosales S. Polio eradication: how long and how much to the end?. Arch Med Res 2013, 10.1016/j.arcmed.2013.05.003.
2. Cochi S.L., Linkins R.W. The final phase of polio eradication: new vaccines and complex choices. J Infect Dis 2012, 205:169-171.
3. Caceres V.M., Sutter R.W. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001, 33:531-541.
4. Duintjer Tebbens R.J., Pallansch M.A., Kalkowska D.A., Wassilak S.G., Cochi S.L., Thompson K.M. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal 2013, 33:703-749.
5. Duintjer Tebbens R.J., Pallansch M.A., Kim J.H., Burns C.C., Kew O.M., Oberste M.S., et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013, 33:680-702.
6. Heinsbroek E., Ruitenberg E.J. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 2010, 28:3778-3783.
7. Davis R., Biellik R. Inactivated polio vaccine: its proposed role in the final stages of polio eradication. Pan Afr Med J 2013, 14:102.
8. Hird T.R., Grassly N.C. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012, 8:e1002599.
9. Dhamodharan A., Proano R.A. Determining the optimal vaccine vial size in developing countries: a Monte Carlo simulation approach. Health Care Manage Sci 2012, 15:188-196.
10. Gyawali S., Rathore D.S., Shankar P.R., Kumar K.V. Strategies and challenges for safe injection practice in developing countries. J Pharmacol Pharmacother 2013, 4:8-12.
11. Jafari H., Deshpande J.M., Sutter R.W., Bahl S., Verma H., Ahmad M., et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 2014, 345:922-925.
12. Kim Y.C., Park J.H., Prausnitz M.R. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012, 64:1547-1568.
13. Ding Z., Van Riet E., Romeijn S., Kersten G.F., Jiskoot W., Bouwstra J.A. Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharm Res 2009, 26:1635-1643.
14. Corbett H.J., Fernando G.J., Chen X., Frazer I.H., Kendall M.A. Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS ONE 2010, 5:e13460.
15. Quan F.S., Kim Y.C., Vunnava A., Yoo D.G., Song J.M., Prausnitz M.R., et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol 2010, 84:7760-7769.
16. Koutsonanos D.G., Vassilieva E.V., Stavropoulou A., Zarnitsyn V.G., Esser E.S., Taherbhai M.T., et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2012, 2:357.
17. Matsuo K., Hirobe S., Yokota Y., Ayabe Y., Seto M., Quan Y.S., et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. J Control Release 2012, 160:495-501.
18. Pattani A., McKay P.F., Garland M.J., Curran R.M., Migalska K., Cassidy C.M., et al. Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. J Control Release 2012, 162:529-537.
19. DeMuth P.C., Min Y., Huang B., Kramer J.A., Miller A.D., Barouch D.H., et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater 2013, 12:367-376.
20. Edens C., Collins M.L., Ayers J., Rota P.A., Prausnitz M.R. Measles vaccination using a microneedle patch. Vaccine 2013, 31:3403-3409.
21. Kommareddy S., Baudner B.C., Bonificio A., Gallorini S., Palladino G., Determan A.S., et al. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine 2013, 31:3435-3441.
22. Hickling J.K., Jones K.R., Friede M., Zehrung D., Chen D., Kristensen D. Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ 2011, 89:221-226.
23. Al-Zahrani S., Zaric M., McCrudden C., Scott C., Kissenpfennig A., Donnelly R.F. Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy. Expert Opin Drug Deliv 2012, 9:541-550.
24. Kang S.M., Song J.M., Kim Y.C. Microneedle and mucosal delivery of influenza vaccines. Expert Rev Vaccines 2012, 11:547-560.
25. Koutsonanos D.G., Compans R.W., Skountzou I. Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol 2013, 785:121-132.
26. Park J.H., Yoon Y.K., Choi S.O., Prausnitz M.R., Allen M.G. Tapered conical polymer microneedles fabricated using an integrated lens technique for transdermal drug delivery. IEEE Trans Biomed Eng 2007, 54:903-913.
27. Chu L.Y., Choi S.O., Prausnitz M.R. Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: bubble and pedestal microneedle designs. J Pharm Sci 2010, 99:4228-4238.
28. Sullivan S.P., Koutsonanos D.G., Del Pilar Martin M., Lee J.W., Zarnitsyn V., Choi S.O., et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010, 16:915-920.
29. Sullivan S., Murthy N., Prausnitz P. Minimally invasive protein delivery with rapidly dissolving polymer microneedle. Adv Mater 2008, 20:933-938.
30. WHO Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis 1997, 175(Suppl. 1):S215-S227.
31. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch für Exp Pathol Pharmakol 1931, 162:480-483.
32. Plotkin S.A. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001, 20:63-75.
33. Bodian D. Experimental studies on passive immunization against poliomyelitis in chimpanzees following subclinical infection. Am J Hyg 1953, 58:81-100.
34. Howe H.A. Immunization against poliomyelitis: poliomyelitis infection in immunized chimpanzees. Ann N Y Acad Sci 1955, 61:1014-1020.
35. Norman J.J., Arya J.M., McClain M.A., Frew P.M., Meltzer M.I., Prausnitz M.R. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine 2014, 32:1856-1862.
36. Li Z.M., Goitz R.J. Biomechanical evaluation of the motor function of the thumb. Technol Health Care 2003, 11:233-243.
37. Dragunsky E., Gardner D., Taffs R., Levenbook I. Transgenic PVR Tg-1 mice for testing of poliovirus type 3 neurovirulence: comparison with monkey test. Biologicals 1993, 21:233-237.
38. Takahashi Y., Misumi S., Muneoka A., Masuyama M., Tokado H., Fukuzaki K., et al. Nonhuman primate intestinal villous M-like cells: an effective poliovirus entry site. Biochem Biophys Res Commun 2008, 368:501-507.
39. Estivariz C.F., Pallansch M.A., Anand A., Wassilak S.G., Sutter R.W., Wenger J.D., et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013, 3:309-315.
40. Thompson K.M., Pallansch M.A., Duintjer Tebbens R.J., Wassilak S.G., Kim J.H., Cochi S.L. Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal 2013, 33:516-543.
41. Sawyer L.A., McInnis J., Albrecht P. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains. Biologicals 1993, 21:169-177.
42. Soonawala D., Verdijk P., Wijmenga-Monsuur A.J., Boog C.J., Koedam P., Visser L.G., et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine 2013, 31:3688-3694.
43. Resik S., Tejeda A., Sutter R.W., Diaz M., Sarmiento L., Alemani N., et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013, 368:416-424.